Genetics Institute, Inc.

Novartis Corporation

Other

Curis, Inc.

Elizabeth A Wang

John Martin Wozney

Vicki A Rosen

Anthony J Celeste

Gordon G Wong

Steven C Clark

Randal J Kaufman

Tobin N Gerhart

Dean M Toriumi

Josephine S D'Alessandro

Mary J Kriz

Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

BMP products

Methods of treatment of periodontal disease

The invention provides methods and compositions for modulating hair growth.

Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto

Purified BMP-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.

BMP-6 proteins

Purified BMP-3 proteins and processes for producing them are disclosed. They may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

Bone morphogenetic protein-3 and compositions

BMP-4 products

BMP-3 products

Purified BMP-5 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.

Methods of administering BMP-5 compositions

A method for preparing and isolating a transformation vector containing CSF/cDNA is described. The method comprises:

DNA encoding GM-CSF and a method of producing GM-CSF protein

A method for purifying CSF protein is described. The method comprises: precipitating the protein with ammonium sulfate at 80% saturation to form a pellet containing the CSF protein; resuspending the pellet in a buffered solution at a pH in the range of about 6 to about 8; applying the buffered solution containing CSF to a chromatographic column, eluting with the buffered solution containing sodium chloride and collecting the fractions having CSF activity; pooling the active fractions, applying them to a C4 reverse phase column and eluting with a 0 to 90% acetonitrile gradient to collect the active fractions. The purified CSF protein has a specific activity of at least about 1.times.10.sup.7 units per mg of protein and preferably at least about 4.times.10.sup.7 units per mg of protein when assayed using the human bone marrow assay.

Isolated native primate GM-CSF protein

Recombinant human granulocyte-macrophage-colony stimulating factor

Purified bone morphogenetic protein (BMP)-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.

Bone morphogenetic protein (BMP)--6

A method for purifying CSF protein is described. The method comprises: precipitating the protein with ammonium sulfate at 80% saturation to form a pellet containing the CSF protein; resuspending the pellet in a buffered solution at a pH in the range of about 6 to about 8; applying the buffered solution containing CSF to a chromatographic columns eluting with the buffered solution containing sodium chloride and collecting the fractions having CSF activity; pooling the active fractions, applying them to a C4 reverse phase column and eluting with a 0 to 90% acetonitrile gradient to collect the active fractions. The purified CSF protein has a specific activity of at least about 1.times.10.sup.7 units per mg of protein and preferably at least about 4.times.10.sup.7 units per mg of protein when assayed using the human bone marrow assay.

Growing community of inventors

Carlisle, MA, United States of America

Elizabeth A Wang